ABCL — AbCellera Biologics Balance Sheet
0.000.00%
- $1.67bn
- $1.12bn
- $28.83m
- 65
- 22
- 99
- 68
Annual balance sheet for AbCellera Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 595 | 723 | 886 | 761 | 626 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 212 | 175 | 103 | 64.4 | 92.1 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 813 | 930 | 1,025 | 872 | 751 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 17.9 | 112 | 217 | 288 | 340 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,006 | 1,319 | 1,541 | 1,488 | 1,361 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 103 | 121 | 118 | 119 | 76.6 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 175 | 293 | 308 | 336 | 304 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 831 | 1,026 | 1,233 | 1,152 | 1,056 |
| Total Liabilities & Shareholders' Equity | 1,006 | 1,319 | 1,541 | 1,488 | 1,361 |
| Total Common Shares Outstanding |